ASCENT-04 Subgroup Analysis Shows Consistent PFS Benefit in Metastatic TNBC
What Is the ASCENT-04 Subgroup Analysis in Metastatic TNBC? The ASCENT-04 trial is a pivotal Phase 3 study evaluating the antibody-drug conjugate (ADC) sacituzumab govitecan [more…]